perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.30.23297662;](https://doi.org/10.1101/2023.10.30.23297662) this version posted October 30, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

1 **Mendelian Randomization Study of Whole Blood Viscosity and** 2 **Cardiovascular Diseases** 3 4 5 Youngjune Bhak^a*****, Albert Tenesaa,b***** 6 7 ^aMRC Human Genetics Unit at the MRC Institute of Genetics and Molecular Medicine, 8 University of Edinburgh, Western General Hospital, Edinburgh, UK. 9 ^bThe Roslin Institute, University of Edinburgh, Easter Bush Campus, Midlothian, EH25 9RG, 10 United Kingdom 11 12 13 14 ***Corresponding author:** 15 Youngjune Bhak Ph.D. 16 The Roslin Institute, Easter Bush Campus, Midlothian, EH25 9RG, United Kingdom 17 Tel.: +44 (0) 747 507 5361 18 Email: ybhak@ed.ac.uk 19 20 Albert Tenesa Ph.D. 21 The Roslin Institute, Easter Bush Campus, Midlothian, EH25 9RG, United Kingdom 22 Tel.: +44 (0) 131 651 9226 23 Email: Albert.Tenesa@ed.ac.uk 24

1 **Abstract**

2 **Aims:** Association between whole blood viscosity (WBV) and an increased risk of 3 cardiovascular disease (CVD) has been reported. However, the causal relationship between 4 WBV and CVD remains not thoroughly investigated. The aim of this study was to investigate 5 the causal relation between WBV and CVD.

6 **Methods:** Mendelian randomization was employed to investigate the casual relationship 7 between WBV and CVD. Calculated WBV, derived polygenic risk score (PRS) for WBV, and 8 medical records from 378,210 individuals participating in the UK biobank study were analyzed.

9 **Results:** The means of calculated WBVs were 16.9 (standard deviation: 0.8) and 55.1 (standard 10 deviation: 17.2) for high shear rate (HSR) and low shear rate (LSR), respectively. 37,859 11 (10.0%) major cardiovascular event (MACE) consisted of 23,894 (6.3%) cases of myocardial 12 infarction (MI), 9,245 (2.4%) cases of ischemic stroke, 10,377 (2.7%) cases of 13 revascularization, and 5,703 (1.5%) cases of Coronary heart disease-related death. WBVs of 14 individuals with PRS above median were significantly higher than the group that were below 15 median for both low shear rate (P<0.001) and high shear rate (P<0.001). The odd ratios (95% 16 confidence intervals) for MACE in the higher WBV group were 1.22 (1.19 - 1.25) and 1.14 17 (1.12 - 1.16), for HSR and LSR, respectively. The higher PRS group was insignificant with all 18 outcomes, for both HSR and LSR.

19 **Conclusions:** The Mendelian randomization analysis conducted in this study does not support 20 a causal relationship between calculated WBV and CVD.

21 **Keywords:** Whole blood viscosity, cardiovascular disease, Mendelian Randomization

22

1 **Introduction**

2 Cardiovascular diseases (CVD), including heart attack and stroke, are one of leading causes of 3 morbidity and mortality globally [1]. Association between the risk of CVD and Whole blood 4 viscosity (WBV), a measure of the thickness and flow resistance of bulk blood, have been 5 reported [2-5]. However, establishing a causal relationship between WBV and CVD remains 6 challenging due to the potential biases from confounding factors in traditional studies lacking 7 randomized trial designs.

8 Mendelian randomization (MR), an epidemiological method, utilizes genetic variants robustly 9 associated with an exposure of interest as instrumental variables (IVs) to investigate the causal 10 effects of risk factors on specific outcomes [6]. The advantage of MR lies in the random 11 assignment of these genetic variants at conception, rendering MR studies less susceptible to 12 confounding factors compared to traditional observational studies [7]. Furthermore, MR is 13 robust against reverse causality since the development of diseases does not alter individuals' 14 genotypes. MR have been utilized to investigate casual relationships of risk factors such as 15 blood pressure [8, 9], obesity [10], type 2 diabetes mellitus [11] and, profile of blood lipids 16 [12-14] in and CVD.

17 The objective of this study was to use MR to examine the causal relationship between WBV 18 and CVD. WBV of individuals was calculated by applying the formula previously reported 19 [15]. Polygenic risk score (PRS), a quantitative genetic risk score, representing the cumulative 20 impact of genetic variants, was derived and used as the instrumental variable in MR. Causal 21 relationship of WBV on risk of CVDs were assessed by comparing individuals stratified by 22 their derived PRS.

23

1 **Methods**

2 **Participants**

3 The UK Biobank (UKB) is a prospective research resource of population-based cohort study 4 that include comprehensive phenotype and genotype data from approximately 500,000 5 participants recruited in 2006 - 2010 residing in England, Scotland, and Wales 6 (www.ukbiobank.ac.uk). This an open-access resource was established to support 7 investigations into the factors influencing various health outcomes [16].

8

9 **Ethics Statement**

10 The UK Biobank project was approved by the National Research Ethics Service Committee 11 North West-Haydock (REC reference: 11/NW/0382). Participants provided written informed 12 consent to participate in the UK Biobank. An electronic signed consent was obtained from the 13 participants. This research was conducted using the UK Biobank Resource under project 44986. 14

15 **Extrapolation of Whole Blood Viscosity**

 WBV was calculated for both low shear rate (LSR) (0.5 sec-1) and high shear rate (HSR) (208 sec-1) from hematocrit (HCT) and total plasma protein concentration (TP) using the validated formulation [15]. HCT was calculated by multiplying red blood cell count by the mean corpuscular volume.

20 HSR: WBV (208 sec⁻¹) =
$$
(0.12 \times
$$
 HCT) + $(0.17$ TP) - 2.07

21 LSR: WBV (0.5 sec⁻¹) =
$$
(1.89 \times
$$
 HCT) + $(3.76$ TP) - 78.42

22

23 **Study outcomes**

1 The data pertaining to each component of the participants' outcomes in the present study was 2 accessible through the UK Biobank study [16]. The primary outcome of the study was major 3 cardiovascular events (MACE), which encompassed a composite outcome involving the 4 occurrence of non-fatal MI, coronary revascularization (defined as "percutaneous transluminal 5 coronary angioplasty, PTCA" or "coronary artery bypass grafting, CABG"), ischemic stroke, 6 or death due to coronary heart disease (CHD).

7 These specific outcomes were defined and categorized as follow: non-fatal MI defined 8 algorithmically by UK Biobank (ICD9: 410.X, 411.0.X, 412.X, 429.79; ICD10: I21.X, I22.X, 9 I23.X, I24.1, I25.2; self-report 20002: 1075), PTCA or CABG (self-report 20004: 1070, 1095, 10 1523; Procedures (OPCS): K50.1, K40.X, K41.X, K42.X, K43.X, K44.X), ischemic stroke 11 (ICD9: 434.X, 436.X; ICD10: I63.X, I64.X; self-report 20002: 1583), and death due to CHD 12 (Death 40001, 40002: I21.X, I22.X, I23.X, I24.X, I25.1, I25.2, I25.3, I25.5, I25.6, I25.8, I25.9) 13 [14].

14

15 **Genetic instrument.**

16 We conducted a split-sample genome wide association study (GWAS) and MR using the UK 17 Biobank dataset. The dataset was randomly split into two halves, and for each half, GWASs 18 for WBVs was performed. The resulting summary statistics from each half were then used to 19 derive the PRS of WBV (WBV-PRS) for the other half to avoid sample overlap [17].

20 To ensure homogeneity, we limited our analyses to unrelated individuals of White British 21 ancestry. Additionally, individuals with more than 10% missing genotypes or those with 22 discrepancies between recorded sex and genetically determined sex were excluded. Following 23 these exclusions, the final dataset consisted of 378,213 participants (Table 1).

24 GWASs were conducted using genotypes of the unrelated White British individuals. White 25 British individuals are inferred from UK Biobank records. The unrelated individuals were

1 identified using the KING software with following options: --unrelated --degree 2 (version 2 2.2.8) [18]. Autosomal genotypes of unrelated White British were further filtered using PLINK 3 software (version 1.90p) with the following options; --geno 0.01, --hwe 1e-15, --maf 0.01, and 4 --mind 0.1 [19]. For the GWASs of WBVs, REGENIE software (version 3.2.2) was utilized 5 with the following option; --apply-rint [20]. Covariates considered in the GWAS included age, 6 age square, genetic principal components 1 to 20, sex, and genotyping array.

7 To select independent instrumental variants for Mendelian randomization, summary statistics 8 were clumped to extract index variants using PLINK software with the following options; -- 9 clump, --clump-p1 0.00000005, --clump-r2 0.001, and --clump-kb 10000 [19]. To avoid the 10 risk of weak instrument bias, variants with F-statistics > 10 were selected [21]. The variants 11 were filtered out if a variant had a reported association with CVD and or factors related with 12 blood viscosity or CVD. The associations were investigated by utilizing PhenoScanner 13 database with the following options; catalogue: diseases & traits, p-value: 5x10-8, proxies - 14 EUR, r^2 : 0.8, and build: 37 [22, 23]. Such factors include obesity [10, 24-26], blood pressure 15 [8, 9, 27], lipid traits [12-14, 28-32], type 2 diabetes mellitus [11, 33, 34], smoking and alcohol 16 intake [35-37]. For HSR, 53 variant from one half split and 50 variants from the other half split 17 passed the filters, respectively. For LSR, 58 variant from one half split and 52 variants from 18 the other half split passed the filters, respectively (Table S1-S4). The filter passed variants were 19 used to derive WBV-PRS. The WBV-PRS was derived using PRSice-2 software (version 2.3.3) 20 by using the summary statistics of variants that passed our filters [38].

21

22 **Statistical analyses**

23 Categorical variables were presented as counts and percentages, continuous variables were 24 presented as mean and standard deviations (SD). Odd ratio (OR) with 95% confidence interval 25 (CI) were analysed using logistic regression. The analysis with WBV-PRS was accompanied

 by adjustments for the split halves, considering them as a batch effect. All significance tests 2 were two-tailed, and statistical significance was determined at $p < 0.05$. The statistical analyses were performed using the R version 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria).

5

6 **Results**

7 A total of 378,210 individuals were included in the study (Table 1). The mean age \pm SD was 8 57.0 \pm 7.9 years. 53.7% of participants were women. The mean \pm SD of calculated WBV were 9 55.1 \pm 17.2 and 16.9 \pm 0.8 for LSR and HSR, respectively. 37,859 (10.0%) of major 10 cardiovascular events, including 23,893 (6.3%) myocardial infarction, 9,245 (2.4%) ischemic 11 stroke, 10,376 (2.7%) revascularization, and 5,703 (1.5%) death due to CHD were recorded. A 12 group of individuals with a WBV-PRS above the median (High WBV-PRS) have higher WBV 13 compared to those with a WBV-PRS equal to or below the median for both HSR (mean 14 difference: 0.11, P<0.001) and LSR (2.58, P<0.001).

15 Associations of the WBV and WBV-PRS groups with the risk of CVDs have exhibited 16 differences. Compared to a group of individual with HSR equal to or below the median, a group 17 of individuals with HSR above the median showed significant association with the increased 18 risk of CVDs including MACE (Odd ratio: 1.22, 95% Confidence interval: 1.19 - 1.25, 19 P<0.001), MI (1.23, 1.20 - 1.27, P<0.001), stroke (1.08, 1.03 - 1.12, P<0.001), 20 revascularization (1.29, 1.23 - 1.34, P<0.001), and death by CVD (1.30, 1.122 - 1.37, P<0.001). 21 High HSR-PRS was not significant in all CVD categories for both unadjusted and adjusted 22 study (Fig. 1A).

23 Compared to a group with LSR equal to or below the median, The group with LSR above the 24 median showed a significant association with the increased risk of CVDs including MACE 25 (1.15, 1.13 - 1.18, P<0.001), MI (1.15, 1.12 - 1.18, P<0.001), revascularization (1.18, 1.13 -

1 1.23, P<0.001), and death by CVD (1.25, 1.18 – 1.32, P<0.001). Effect of High LSR-PRS was 2 insignificant in all CVD for both unadjusted and adjusted study (Fig. 1B).

3

4 **Discussion**

5 This study used MR to investigate the potential causal association between WBV and CVD. 6 The result from this study indicated insufficient evidence to substantiate a causal link between 7 WBV and the risk of CVD.

8 WBV is susceptible to various influencing factors. Notably, WBV demonstrate non-Newtonian 9 fluid behaviour. Under conditions of low shear rates, blood cells tend to aggregate, leading to 10 an elevation in viscosity. Conversely at HSR, the opposite phenomenon occurs [39-41]. WBV 11 has been noted to exhibit association with CVD and cardiovascular risk factors in previous 12 studies [3, 42, 43]. However, upon adjustments for these risk factors, the association between 13 WBV and CVD was found to be statistically non-significant in the subsequent study [44]. The 14 not significant association following adjustments remained consistently evident in this study 15 using MR.

16 However, the study result should be interpreted and considered carefully since we have not 17 utilized directly measured WBV. While the formula employed in our study has undergone 18 validation and has been applied in previous researches [15, 45, 46], it does not considered 19 factors for WBV such as blood cell aggregability and deformability [47]. To establish a robust 20 causal link between WBV and both CVD and CVD-related factors, future studies should 21 incorporate measured WBV values, taking into account these critical variables.

22

23

24 **Declarations**

25 **Availability of data and materials**

 Our data is available as a part of the UK Biobank project. Details of procedures for accessing the UK Biobank data can be found here: https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access

Competing interests:

The authors have declared that no competing interests exist.

Funding:

 This project was funded by the National Institute for Health Research (NIHR) Artificial Intelligence and Multimorbidity: Clustering in Individuals, Space and Clinical Context (AIM-CISC) grant NIHR202639. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgments

 This work used the Edinburgh Compute and Data Facility (ECDF) (<http://www.ecdf.ed.ac.uk/>). This research has been conducted using the UK Biobank Resource project 44986. For the purpose of open access, the author has applied a CC-BY public copyright licence to any Author

Accepted Manuscript version arising from this submission.

Authors' contributions

- 21 Conceptualization: Y.B.
- 22 Data curation: Y.B.

- 1 Formal analysis: Y.B.
- 2 Funding Acquisition: A.T.
- 3 Investigation: Y.B.
- 4 Methodology: Y.B.
- 5 Project Administration: Y.B., A.T.
- 6 Resources: Y.B.
- 7 Software: Y.B.
- 8 Supervision: A.T.
- 9 Visualization: Y.B.
- 10 Writing original draft: Y.B.
- 11 Writing review & editing: Y.B., A.T.
- 12
- 13

14 **Reference**

- 16 *groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study*
- 17 *2010.* The lancet, 2012. **380**(9859): p. 2095-2128.
- 18 2. Lowe, G., et al., *Blood viscosity and risk of cardiovascular events: the Edinburgh*
- 19 *Artery Study.* British journal of haematology, 1997. **96**(1): p. 168-173.

- 1 21. Pierce, B.L., H. Ahsan, and T.J. VanderWeele, *Power and instrument strength* 2 *requirements for Mendelian randomization studies using multiple genetic variants.* 3 International journal of epidemiology, 2011. **40**(3): p. 740-752.
- 4 22. Staley, J.R., et al., *PhenoScanner: a database of human genotype–phenotype* 5 *associations.* Bioinformatics, 2016. **32**(20): p. 3207-3209.
- 6 23. Kamat, M.A., et al., *PhenoScanner V2: an expanded tool for searching human* 7 *genotype–phenotype associations.* Bioinformatics, 2019. **35**(22): p. 4851-4853.
- 8 24. Elagizi, A., et al., *An overview and update on obesity and the obesity paradox in* 9 *cardiovascular diseases.* Progress in cardiovascular diseases, 2018. **61**(2): p. 142-150.
- 10 25. Khan, S.S., et al., *Association of body mass index with lifetime risk of cardiovascular* 11 *disease and compression of morbidity.* JAMA cardiology, 2018. **3**(4): p. 280-287.
- 12 26. Guiraudou, M., et al., *Obesity-related increase in whole blood viscosity includes* 13 *different profiles according to fat localization.* Clinical Hemorheology and 14 Microcirculation, 2013. **55**(1): p. 63-73.
- 15 27. Letcher, R.L., et al., *Direct relationship between blood pressure and blood viscosity in* 16 *normal and hypertensive subjects: role of fibrinogen and concentration.* The American 17 journal of medicine, 1981. **70**(6): p. 1195-1202.
- 18 28. Ference, B.A., et al., *Low-density lipoproteins cause atherosclerotic cardiovascular* 19 *disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus* 20 *statement from the European Atherosclerosis Society Consensus Panel.* European heart
- 21 journal, 2017. **38**(32): p. 2459-2472.
- 22 29. Jeong, S.M., et al., *Effect of change in total cholesterol levels on cardiovascular disease* 23 *among young adults.* Journal of the American Heart Association, 2018. **7**(12): p. 24 e008819.

- 1 30. Laufs, U., et al., *Clinical review on triglycerides.* European heart journal, 2020. **41**(1): 2 p. 99-109c.
- 3 31. Kosmas, C.E., et al., *High-density lipoprotein (HDL) functionality and its relevance to* 4 *atherosclerotic cardiovascular disease.* Drugs in context, 2018. **7**.
- 5 32. Irace, C., et al., *Influence of blood lipids on plasma and blood viscosity.* Clinical 6 Hemorheology and Microcirculation, 2014. **57**(3): p. 267-274.
- 7 33. Liu, B., et al., *Genetically predicted type 2 diabetes mellitus liability, glycated* 8 *hemoglobin and cardiovascular diseases: a wide-angled Mendelian randomization* 9 *study.* Genes, 2021. **12**(10): p. 1644.
- 10 34. Andrea, V. and I. Timan. *Relationship between diabetes mellitus and blood viscosity as* 11 *measured by the digital microcapillary® system*. in *Journal of Physics: Conference*
- 12 *Series*. 2018. IOP Publishing.
- 13 35. Rosoff, D.B., et al., *Evaluating the relationship between alcohol consumption, tobacco* 14 *use, and cardiovascular disease: a multivariable Mendelian randomization study.* 15 PLoS medicine, 2020. **17**(12): p. e1003410.
- 16 36. Lowe, G., et al., *The effects of age and cigarette-smoking on blood and plasma viscosity* 17 *in men.* Scottish medical journal, 1980. **25**(1): p. 13-17.
- 18 37. Hamazaki, T. and H. Shishido, *Increase in blood viscosity due to alcohol drinking.* 19 Thrombosis Research, 1983. **30**(6): p. 587-594.
- 20 38. Choi, S.W. and P.F. O'Reilly, *PRSice-2: Polygenic Risk Score software for biobank-*21 *scale data.* Gigascience, 2019. **8**(7): p. giz082.
- 22 39. Pop, G., et al., *The clinical significance of whole blood viscosity in (cardio) vascular* 23 *medicine.* Netherlands heart journal, 2002. **10**(12): p. 512.
- 24 40. Naghedi-Baghdar, H., et al., *Effect of diet on blood viscosity in healthy humans: a* 25 *systematic review.* Electronic physician, 2018. **10**(3): p. 6563.

- 1 41. Nwose, E.U., *Cardiovascular risk assessment and support techniques: whole blood* 2 *viscosity assessment issues I: extrapolation chart and reference values.* North 3 American Journal of Medical Sciences, 2010. **2**(4): p. 165.
- 4 42. Lowe, G., et al., *Cardiovascular risk and haemorheology–results from the Scottish* 5 *Heart Health Study and the MONICA Project, Glasgow.* Clinical Hemorheology and 6 Microcirculation, 1988. **8**(3-4): p. 517-524.
- 7 43. Woodward, M., et al., *Associations of blood rheology and interleukin‐6 with* 8 *cardiovascular risk factors and prevalent cardiovascular disease.* British journal of 9 haematology, 1999. **104**(2): p. 246-257.
- 10 44. Peters, S.A., et al., *Plasma and blood viscosity in the prediction of cardiovascular* 11 *disease and mortality in the Scottish Heart Health Extended Cohort Study.* European
- 12 journal of preventive cardiology, 2017. **24**(2): p. 161-167.
- 13 45. Høieggen, A., et al., *Whole-blood viscosity and the insulin-resistance syndrome.* 14 Journal of hypertension, 1998. **16**(2): p. 203-210.
- 15 46. Moan, A., et al., *Relationship between hemorrheologic factors and insulin sensitivity* 16 *in healthy young men.* Metabolism, 1994. **43**(4): p. 423-427.
- 17 47. Lowe, G., *1 Blood rheology in vitro and in vivo.* Bailliere's clinical haematology, 1987.
- 18 **1**(3): p. 597-636.
- 19
- 20
- 21
- 22
- 23
- 24
- 25

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.30.23297662;](https://doi.org/10.1101/2023.10.30.23297662) this version posted October 30, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

- It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .
- 1
-
-
- 2
-
- 3
-
- 4
- 5
- 6

7 **Figure legends**

8 **Figure 1***.* **Association of the WBV and WBV-PRS with the risk of cardiovascular events.**

9 Panel A shows the associations between high HSR and high HSR-PRS with the risk of 10 cardiovascular events, and panel B shows the associations between high LSR and high LSR-11 PRS with the risk of cardiovascular events. The boxes represent point odd ratio estimates of 12 the effect, and the lines represent 95% confidence intervals. MACE denotes major 13 cardiovascular event, MI myocardial infarction, WBV whole blood viscosity, WBV-PRS

- 14 polygenic risk score for whole blood viscosity.
- 15

16

17 **Tables**

18 **Table 1** Baseline characteristics.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.30.23297662;](https://doi.org/10.1101/2023.10.30.23297662) this version posted October 30, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

1 Plus–minus values are means ±SD. HDL denotes high-density lipoprotein, LDL low-density lipoprotein, LSR

2 low-shear rate, HSR high shear rate, and CHD coronary heart disease. Major cardiovascular event includes

3 myocardial infarction, ischemic stroke, revascularization, and death due to CHD

WBV-PRS over the median . .

Figure